ArticlePharmacology research & perspectives2026
Ginsenosides Rb1 and Rg1 Suppress Lipopolysaccharide-Induced Inflammatory Gene Expression in Microglia and Astrocytes, Unlike Rb2.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Neuroinflammation, mediated by activated microglia and astrocytes, contributes to the progression of neurodegenerative diseases. Ginsenosides derived from Panax ginseng possess anti-inflammatory properties. However, the comparative efficacy of structurally distinct ginsenosides and their activity across multiple glial cell types remains incompletely understood. In this study, we systematically compared the effects of ginsenosides Rb1 (protopanaxadiol-type), Rb2 (protopanaxadiol-type), and Rg1 (protopanaxatriol-type) in lipopolysaccharide (LPS)-activated BV2 microglia and C8-D1A astrocytes. Following LPS stimulation, cells were treated with ginsenosides, and inflammatory responses were assessed by cell viability assay, real-time polymerase chain reaction, enzyme-linked immunosorbent assay (ELISA), and western blotting. None of the three ginsenosides up to 20 μM concentration reduced cell viability. Rb1 and Rg1 suppressed LPS-induced expression of proinflammatory genes, including Il-6, Il-1β, and Cox-2, across multiple concentrations, with inhibitory effects particularly notable at 5 and 10 μM. ELISA further confirmed that Rb1 and Rg1 reduced interleukin (IL)-6 and IL-1β secretion in both glial cell types. In contrast, Rb2 showed limited and inconsistent anti-inflammatory effects, despite being structurally similar to Rb1. Rb1 and Rg1 reduced LPS-induced phosphorylation of nuclear factor kappa B (NF-κB) in nuclei of both cell types, whereas Rb2 suppressed NF-κB phosphorylation only in BV2 microglia. Rb1 reduced AKT and p38 phosphorylation in C8-D1A astrocytes, indicating compound- and cell-type-specific regulation of inflammatory signaling. Notably, Rb2-mediated NF-κB suppression did not translate into broad inhibition of inflammatory gene or cytokine expression. These findings identify Rb1 and Rg1 as ginsenosides with broad anti-inflammatory activity in microglia and highlight glycosylation-dependent functional differences among structurally related ginsenosides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.